標靶蛋白分解（TPD）市場規模、佔有率及成長分析（按類型、治療領域、給藥途徑、最終用途及地區分類）－2026-2033年產業預測

全球標靶蛋白質分解市場規模預計在 2024 年達到 6.4602 億美元，從 2025 年的 8.2626 億美元成長到 2033 年的 59.1674 億美元，在預測期（2026-2033 年）內複合年成長率為 27.9%。

全球標靶蛋白分解市場正日益受到關注，它是一種創新的藥物研發策略，利用小分子化合物特異性清除疾病相關蛋白。該方法的關鍵優勢在於其廣泛的適用性，能夠治療多種傳統上“難治性疾病”，包括某些癌症和遺傳性疾病。標靶蛋白分解的選擇性可最大限度地減少脫靶效應，從而提高療效並降低副作用。此外，該療法的持久性也得到提升，其療效持續時間比傳統藥物更長，從而減少了給藥頻率，提高了患者的依從性。這種全新的作用機制為聯合治療開啟了可能性，進一步拓展了治療選擇，並推動了標靶蛋白分解市場的成長。

全球標靶蛋白分解市場促進因素

全球標靶蛋白分解市場正經歷顯著成長，這主要得益於人們對更有效疾病治療方案的需求不斷成長。癌症、遺傳性疾病和自體免疫疾病等病症對患者健康造成重大影響，凸顯了針對這些疾病根本原因的治療方法的緊迫性。標靶蛋白分解技術可望選擇性地分解疾病相關蛋白，在提高療效的同時減少副作用。這種創新方法能夠開發出針對有害蛋白質且不損傷健康細胞的藥物，從而在改善患者預後的同時最大限度地減少不良反應。此外，這種標靶機制為以往被認為「無法治癒」的疑難雜症提供了解決方案，開闢了藥物研發的新途徑，並為治療選擇有限的患者帶來了新的希望。

抑制全球標靶蛋白質分解市場

由於靶向蛋白分解領域固有的複雜性，該市場面臨巨大的挑戰。這種創新方法需要對蛋白質結構和功能有深入的了解，以及先進的藥物設計和開發技術。圍繞靶向蛋白分解開發新治療方法的過程通常複雜且漫長，這可能會減緩該領域的進展。開發人員必須透徹理解疾病的生物機制和所涉及的特定蛋白質，才能創造出有效的解決方案。此外，設計能夠與細胞分解機制相互作用的高效、選擇性強且穩定的分子至關重要，這需要大量的研發投入。

全球標靶蛋白分解市場趨勢

全球標靶蛋白分解市場正呈現顯著的趨勢，即開發口服藥物製劑，這主要得益於患者對更便捷治療方法日益成長的需求。這些口服療法具有無與倫比的便利性，使患者無需頻繁就醫或接受侵入性治療即可有效控制病情。藥廠正優先研發能夠有效透過消化器官系統並利用緩釋機制維持療效的口服藥物。這項轉變有望透過提供更易於管理且更便捷的治療方案來改善患者照護，並提高患者的依從性，而這對於治療的成功至關重要。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管分析
• 專利分析

全球標靶蛋白分解（TPD）市場規模（按類型和複合年成長率分類）（2026-2033 年）

• 地塞米胺
• 免疫調節藥物（IMIDS）
• 蛋白水解靶向嵌合體分子（PROTACS）
• 突發性視網膜退化症候群（SARDS）
• 選擇性雌激素受體分解劑（SERDS）
• 其他

全球標靶蛋白分解（TPD）市場規模（依治療領域分類）及複合年成長率（2026-2033 年）

• 發炎性疾病
• 神經系統疾病
• 腫瘤疾病
• 呼吸系統疾病
• 其他

全球標靶蛋白分解（TPD）市場規模（按給藥途徑和複合年成長率分類）（2026-2033 年）

• 口服
• 靜脈注射
• 其他

全球標靶蛋白分解 (TPD) 市場規模（按最終用途和複合年成長率分類）（2026-2033 年）

• 製藥和生物技術公司
• 學術和研究機構
• 醫院和臨床檢查室
• 其他

全球標靶蛋白分解（TPD）市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
• 2023-2025年營收年比比較

主要企業簡介

• Arvinas（USA）
• Kymera Therapeutics（USA）
• Nurix Therapeutics（USA）
• C4 Therapeutics（USA）
• Foghorn Therapeutics（USA）
• Zymeworks（Canada）
• Bristol-Myers Squibb（USA）
• Pfizer（USA）
• AbbVie（USA）
• Sanofi（France）
• Roche（Switzerland）
• AstraZeneca（UK）
• Vertex Pharmaceuticals（USA）
• Amgen（USA）
• Takeda Pharmaceutical（Japan）
• Novartis（Switzerland）
• Gilead Sciences（USA）
• Merck & Co.（USA）
• Janssen Pharmaceuticals（Johnson & Johnson）（USA）
• BeiGene（China）

結論與建議

Global Targeted Protein Degradation Market size was valued at USD 646.02 Million in 2024 and is poised to grow from USD 826.26 Million in 2025 to USD 5916.74 Million by 2033, growing at a CAGR of 27.9% during the forecast period (2026-2033).

The market for Global Targeted Protein Degradation is gaining traction as an innovative drug development strategy that employs small molecules to specifically eliminate disease-related proteins. Key benefits of this approach include its broad applicability, allowing treatment of various conditions previously deemed "undruggable," such as certain cancers and genetic disorders. The selectivity offered by targeted protein degradation minimizes off-target effects, enhancing the therapeutic impact while reducing side effects. Additionally, treatments can demonstrate increased durability, maintaining efficacy longer than conventional drugs, which may lead to less frequent dosing and improved patient adherence. This novel mode of action paves the way for combination therapies, further broadening the therapeutic landscape and driving growth within the targeted protein degradation market segment.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Targeted Protein Degradation market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Targeted Protein Degradation Market Segments Analysis

Global Targeted Protein Degradation Market is segmented by type, therapeutic area, route of administration, end use and region. Based on type, the market is segmented into degronimids, immunomodulatory drugs (IMIDS), proteolysis-targeting chimeric molecules (PROTACS), sudden acquired retinal degeneration syndrome (SARDS), selective estrogen receptor degraders (SERDS) and others. Based on therapeutic area, the market is segmented into inflammatory disorders, neurological disorders, oncological disorders, respiratory disorders and others. Based on route of administration, the market is segmented into oral, intravenous and others. Based on end use, the market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, hospital & clinical laboratories and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Targeted Protein Degradation Market

The Global Targeted Protein Degradation market is experiencing considerable growth driven by the increasing demand for more effective therapeutic options across various diseases. Conditions such as cancer, genetic disorders, and autoimmune disorders significantly affect patient well-being, highlighting the urgent need for treatments that target the root causes of these illnesses. Targeted protein degradation technology holds promise in selectively degrading disease-related proteins, thereby offering improved treatment efficacy with potentially fewer side effects. This innovative approach facilitates the creation of drugs that focus on harmful proteins while leaving healthy cells intact, minimizing adverse reactions and enhancing patient outcomes. Furthermore, this targeted mechanism presents solutions for challenging diseases previously deemed "undruggable," unlocking new avenues for drug development and providing renewed hope for patients with limited treatment options.

Restraints in the Global Targeted Protein Degradation Market

The targeted protein degradation market encounters significant challenges due to the inherent complexity of the field. This innovative approach necessitates an in-depth comprehension of protein structure and function, along with sophisticated drug design and development skills. The process of creating new therapies centered on targeted protein degradation is often intricate and lengthy, causing potential delays in advancements within the sector. Developers must thoroughly understand disease biology and the specific proteins involved to craft effective solutions. Additionally, the design of potent, selective, and stable molecules that can interact with the cellular degradation machinery is essential, demanding substantial investment in research and development.

Market Trends of the Global Targeted Protein Degradation Market

The Global Targeted Protein Degradation market is witnessing a significant trend towards the development of oral drug formulations, driven by the increasing demand for more patient-friendly treatment options. These oral therapies offer unparalleled convenience, allowing patients to manage their conditions without the need for frequent clinic visits or invasive procedures. Pharmaceutical companies are prioritizing research to create oral drugs that can effectively navigate the digestive system and maintain therapeutic efficacy through sustained release mechanisms. This shift not only enhances patient compliance, vital for treatment success, but also promises to transform patient care by facilitating more manageable and accessible therapeutic options for a variety of diseases.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis
• Patent Analysis

Global Targeted Protein Degradation Market Size by Type & CAGR (2026-2033)

• Market Overview
• Degronimids
• Immunomodulatory Drugs (IMIDS)
• Proteolysis-Targeting Chimeric Molecules (PROTACS)
• Sudden Acquired Retinal Degeneration Syndrome (SARDS)
• Selective Estrogen Receptor Degraders (SERDS)
• Others

Global Targeted Protein Degradation Market Size by Therapeutic Area & CAGR (2026-2033)

• Market Overview
• Inflammatory Disorders
• Neurological Disorders
• Oncological Disorders
• Respiratory Disorders
• Others

Global Targeted Protein Degradation Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Intravenous
• Others

Global Targeted Protein Degradation Market Size by End Use & CAGR (2026-2033)

• Market Overview
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Hospital & Clinical Laboratories
• Others

Global Targeted Protein Degradation Market Size & CAGR (2026-2033)

• North America (Type, Therapeutic Area, Route of Administration, End Use)
  • US
  • Canada
• Europe (Type, Therapeutic Area, Route of Administration, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Therapeutic Area, Route of Administration, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Therapeutic Area, Route of Administration, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Therapeutic Area, Route of Administration, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
• Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Arvinas (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kymera Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nurix Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• C4 Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Foghorn Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zymeworks (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Janssen Pharmaceuticals (Johnson & Johnson) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BeiGene (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations